In vitro determination of the apoptotic effect of heparin on lymphoblasts using DNA analysis and measurements of Fas and Bcl-2 proteins by flow cytometry

Pediatric Hematology and Oncology

Volumn 21, Issue 5, 2004, Pages 383-391

  Erduran, Erol ^a   Tekelioglu, Yavuz ^a   Gedik, Yusuf ^a   Bektaş, Ismail ^a   Hacisalihoglu, Sadan ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Bcl 2; Fas; Heparin

Indexed keywords

FAS ANTIGEN; HEPARIN; PROTEIN BCL 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DNA DETERMINATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; LYMPHOBLAST; MEASUREMENT; PROTEIN EXPRESSION;

APOPTOSIS; BONE MARROW; CHILD; CHILD, PRESCHOOL; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HEPARIN; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 3042804046     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010490457051     Document Type: Article

References (29)

1. Mandal AK, Lyden TW, Saklayen MG. Heparin lowers blood pressure: biological and clinical perspectives. Kidney Int. 1995;47:1017-1022.
2. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood. 1993;82:3253-3258.
3. Fedarko NS, Ishihara M, Courad HE. Control of cell division of hepatoma cells by exogeneous heparin sulfate proteoglycan. J Cell Physiol. 1989;139:287-294.
4. Reilly CF, Fritze LMS, Rosenberg RD. Heparin inhibition of smooth muscle cell proliferation: a cellular site of action. J Cell Physiol. 1986;129:11-19.
5. Erduran E, Tekelioglu Y, Gedik Y, Yildiran A. Apoptotic effects of heparin on lymphoblasts, neutrophils and mononuclear cells: results of a preliminary in vitro study. Am J Hematol. 1999;61:90-93.
6. Manaster J, Chezar J, Schurtz-Swirski R, Shapiro G, Tendler Y, Kristal B, Shasha SM, Sela S. Heparin induces apoptosis in human peripheral blood neutrophils. Br J Haematol. 1996;94:48-52.
7. Castellot J, Wong K, Herman B, et al. Binding and internalization heparin by vascular smooth muscle cell. J Cell Physiol. 1985;124:13-20.
8. Strasser A, O'Conner L, Dixit VM. Apoptosis signaling. Annu Rev Biochem. 2000;69:217-245.
9. Alnemri ES, Livingstone DJ, Nicholson DW, et al. Human ICE/CED-3 proteas nomenclature. Cell. 1996;87:171.
10. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci. 1997;22:299-306.
11. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312-1316.
12. Wickremasinghe RG, Hoffbrand AV. Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Blood. 1999;93:3587-3600.
13. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interact with the death domain of fas and initiates apoptosis. Cell. 1995;81:513-523.
14. Monaghan P, Robertson D, Amos TA, Dyer MJ, Mason DY, Greaver MF. Ultrastructural localization of bcl-2 protein. J Histochem Cytochem. 1992;40:1819-1825.
15. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.
16. Saunders BD, Trapp RG. Decisions about two independent groups. In: Basic and Clinical Bioistatistics. ed. 2. London: Prentice-Hall; 1994:112-119.
17. Ormerod MG. The study of apoptotic cells by flow cytometry. Leukemia. 1998;12:1013-1025.
18. Daryzynkiewicz Z, Bruno S, Del Bino G, Hotz MA, Lassota P, Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry. 1992;13:795-808.
19. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
20. Fleisher TA. Apoptosis. Ann Allergy Asthma Immunol. 1997;78:245-250.
21. Cohen GM, Sun XM, Snowden RT, Dinsdale D, Skilleter DN. Key morphological features of apoptosis may occur in the abscence of internucleosomal DNA degradation. Biochem J. 1992;286:331-334.
22. Nagata S, Golstein P. The fas death factor. Science. 1995;267:1449-1456.
23. Munker R, Lubbert M, Yonehara S, Tuchnitz A, Wilmanns W. Expression of the fas antigen on primary human leukemia cells. Ann Hematol. 1995;70:15-17.
24. Robertson MJ, Manley TJ, Pichert G, Cameron C, Levine H, Ritz J. Functional consequences of APO-1/fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma. 1995;17:51-61.
25. Debatin KM, Krammer PH. Resistance to APO-1 (CD95) induced apoptosis in T-ALL determined by a bcl-2 independent anti-apoptotic program. Leukemia. 1995;9:815-820.
26. Baryshnikov A, Polosukhina ER, Tupitsin NN, et al. CD95 (fas/APO-1) is a new prognostic marker for blast cells of acute lymphoblastic leukaemia patient. Adv Exp Med Biol. 1999;457:251-258.
27. Beltinger C, Bohler T, Karawajew L, Ludwig WD, Debatin KM. Mutation analysis of CD95 (APO-1/fas) in childhood B lineage acute lymphoblastic leukaemia. Br J Haematol. 1998;102:722-728.
28. Barcena A, Park SW, Banapour B, Muench MO, Mechetner E. Expression of fas/CD95 and bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Blood. 1996;88:2013-2025.
29. Karawajew L, Wuchter C, Ruppert V, Drexler H, Gruss HJ, Ludwig WD. Differential CD95 expression in T and B lineage acute lymphoblastic leukemia cells. Leukemia. 1997;11:1245-1252.